The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with LY3841136 compared with placebo in adult participants with obesity or overweight. The study will last about 64 weeks and may include up to 17 visits.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
263
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 48
Change from Baseline in Body Weight
Time frame: Baseline, Week 48
Percentage of Participants Who Achieve ≥5% Body Weight Reduction
Time frame: Baseline to Week 48
Percentage of Participants Who Achieve ≥10% Body Weight Reduction
Time frame: Baseline to Week 48
Change from Baseline in Body Mass Index (BMI)
Time frame: Baseline, Week 48
Pharmacokinetics (PK): Area Under the Curve (AUC) of LY3841136
Time frame: Baseline to Week 48
PK: Maximum Concentration (Cmax) of LY3841136
Time frame: Baseline to Week 48
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
Chandler, Arizona, United States
Headlands Research - Scottsdale
Scottsdale, Arizona, United States
The Institute for Liver Health II dba Arizona Liver Health-Tucson
Tucson, Arizona, United States
NorCal Medical Research, Inc
Greenbrae, California, United States
Velocity Clinical Research, Huntington Park
Huntington Park, California, United States
Peninsula Research Associates
Rolling Hills Estates, California, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Northeast Research Institute (NERI)
Fleming Island, Florida, United States
Suncoast Clinical Research, Inc.
New Port Richey, Florida, United States
Charter Research - Winter Park
Orlando, Florida, United States
...and 36 more locations